Red C Biotech
RedC Biotech is developing an innovative process for the industrial production of universal red blood cells (RBCs) to be used for life-saving blood transfusions and advanced therapies. RBCs carry oxygen to the body and blood transfusions are a cornerstone in the treatment of trauma, childbirth, surgery, and treatments for chronic anemia in cancer patients, Sickle Cell Anemia and Thalassemia sufferers. 120 million blood units are donated every year, yet additional tens of millions are still needed in low-income regions. RedC's production process involves a state-of-the-art high-density culture of stem cells that are differentiated to mature oxygen carrying RBCs that will be packed and shipped to hospitals around the world. As production volumes will increase, RedC Biotech will meet cost targets that will allow solving the severe RBC transfusion shortage around the world.
גיוס השקעה או תמיכה כספית
RedC's RBC transfusions solution will directly support the UN SDG 3.1, 3.2 and 3.3 for reducing maternal mortality, eliminating preventable deaths of newborns and children under 5 years of age birth, and help with ending the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases, and other communicable diseases, respectively. RedC's RBC transfusions will indirectly contribute to SDGs 3.6 and 3.8, halving the number of global deaths and injuries from road traffic accidents and helping in delivering universal, affordable, and quality health coverage.